Dear Colleagues,
It is with great pleasure that we invite you to attend The 2nd World Congress on Advanced Treatments in Skin Cancer (Skin-Cancer2020) which will take place 2-3 April 2020 in Berlin, Germany.
Skin-Cancer2020 follows the success of the 2019 Congress and will continue to review and focus on the recent advancements in the diagnosis, treatment and management of various skin cancers such as basal and squamous cell carcinomas, melanoma, merkel cell carcinoma, cutaneous lymphomas and other rare skin cancers.
The Congress will welcome dermatologists, oncology professionals, skin cancer specialists, treatment experts, nurses, industry leaders and other experts to the majestic city of Berlin.
Prof. Dr. Joseph Alcalay
Congress Chair
Meet the Speakers

Medical University of Vienna, Austria

Inselspital, Germany

University Hospital Birmingham , UK

St. Josef-Hospital, Germany
Sponsors & Exhibitors
All SponsorsCongress Program

University Hospital Zurich, Switzerland

New York University School of Medicine, USA

Berlin, Germany

Sheba Medical Center, Israel

University Hospital Zurich, Switzerland

Sheba Medical Center, Israel

Tel Aviv University, Israel
Prof. Ronit Satchi-Fainaro, Ph.D.
Head, Cancer Research and Nanomedicine Laboratory; The Hermann and Kurt Lion Chair in Nanosciences and Nanotechnologies; Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Room 607, Tel Aviv University, Tel-Aviv 69978, Israel http://SatchiFainaroLab.com
Despite the remarkable efficiency of immune checkpoint modulators against metastatic melanoma, there is a low percentage of responders and clinical trials report severe immune-mediated side effects and disease relapse. Recent evidences show that non-tumor cells within the tumor microenvironment (TME), including tumor vasculature and immune stromal cells, dictate the overall therapeutic efficacy. We are exploring off-the-shelf and cost-effective nano-sized carriers that combine a cancer nano-vaccine with the targeted inhibition of molecular and/or cellular immune suppressive players. These precision nano-sized medicines aim to re-educate and harness patient T-cell response against tumors, leading to an immunological memory able to control tumor relapse without any follow-up treatment. The design of these advanced nano-immunotherapies is guided by the identification of lead immune suppressor factors and tumor specific antigens using novel 3D bio-printed tumor-immune spheroids developed in our lab. Our first nano-immunotherapy candidates sensitized melanoma mouse models to immune-checkpoint modulators, dramatically increasing disease-free survival rates.

Hospital Clinic de Barcelona, Spain
Ex vivo confocal microscopy is an imaging technique that allows an instantaneous analysis of fresh excised tissues. The first applications were on the field of Mohs surgery, but with the advancement of the technology, new applications have been proposed. This method opened a new door in the histological analysis of samples.

Helios University Hospital Wuppertal, Germany
The term phodtodynamic goes back to Hermann von Tappeiner in 1904 describing a photooxidative process through which reactive oygen species is generated through absorption of light by a photosensitizer. Already in those days several dermatological condition, i.e., basal call carcinoma and lupus vulgaris were experimentally treated on this basis by photodynamic therapy.
However, only one hundred years later photosensitizers (porphyrins) were officially approved in clinical dermatology. The development of a topical pro-drug (aminolevolinic acid. ALA) by James Kennedy, who upon the 1990s treated superficial cutaneous tumors with externally applied ALA and visible light, represented the breakthrough for topical PDT.
Today, topical photodynamic therapy is approved for actinic keratoses, superficial basal cell carcinoma, and Bowen’s disease .
In several consensus papers and guidelines PDT is regarded as first line therapy in these indications. However, a balanced review of all treatment options for each indication is needed in ordert o offer the best choice of different therapeutical approaches to a given patient.
Effectivity (cure rate) as well as side effects have to be taken into consideration when choosing a modality.
Recent developments include different pretreatment options, like calcipotriol or fraxel laser before the PDT in ordert o enhance effectivity with promising results.
The development of daylight PDT has brought a significant reduction oft he main disagreeable side effect of PDT: Pain.
In order to maintain a good control of he complex steps in PDT, light sources have been developed simulating daylight. Therefore, today we can offer an almost painless PDT under controlled conditions with equal results as conventional PDT.

University Hospital Birmingham , UK
Prof. Julia Scarisbrick
Primary cutaneous lymphoma is rare. They may be divided into primary cutaneous B-cell lymphoma (PC-BCL) and primary cutaneous T-cell lymphomas (PC-TCL). Both are rare less with an incidence of <10 per million. T-cell lymphomas are more prevalent accounting for ~65% of all skin lymphomas. Most are mycosis fungoides (MF).
PC-BCL is divided into 3 subtypes. The low-grade primary cutaneous lymphomas include follicle centre lymphoma (PCFCL) and primary cutaneous marginal zone lymphoma (PCMZL), which can occur at any age, and the rare, primary cutaneous, diffuse, large B-cell lymphoma (PCLBCL) leg type, which occurs typically in elderly female patients and is the aggressive subtype requiring similar treatment to systemic BCL with CHOP and rituximab. The majority of the low grade subtypes PCMZL and PCFCL may be treated with local surgery or skin directed therapy. Cutaneous relapses are common but systemic spread is rare.
MF tends to be indolent with a long course with disease limited to skin but a small number present in/progress to advanced disease with aggressive skin lesions (tumours or erythroderma) or nodal/visceral spread and a poor prognosis. The early stages may be treated with skin directed therapy but refractory/aggressive PC-TCL requires systemic therapy firstly with immunotherapy and then chemotherapy. No treatments have been shown to be disease modifying and those with advanced disease and good performance status may be considered for allogeneic bone marrow transplant. The aggressive subtypes (Sezary syndrome, gamma-delta lymphoma, aggressive CD8+ve lymphoma) require systemic chemotherapy and consideration of allogenic bone marrow transplant in first remission.

Rabin Medical Center, Beilinson Hospital, Israel

Aristotle University of Thessaloniki, Greece

Medical University of Vienna, Austria

Municipal Hospital Munich, Germany

Rabin Medical Center, Israel

The Skin Doctors’ Center, Italy
Leonardo Marini, SDC The Skin Doctors’ Center Trieste (I)
Photodynamic therapy is a well-established, non-invasive treatment option for a variety of dermatologic disorders, including actinic keratosis and photo-aging. Conventional PDT, usually associated with significant levels of pain during and immediately after light-activating procedures, has been recently innovated with the introduction of the so-called daylight approach. PDT requires three major “ingredients”: a topical photosensitizer – most commonly 5-ALA or 5-MAL, an appropriate light source, and good levels of tissue oxygen. Various pre-treatment ancillary procedures have been proposed to improve trans-cutaneous penetration and localized absorption of photosensitizers, leading to significant improvements of treatment efficacy. There is no wide agreement to the organization of the sequential steps characterizing PDT: skin preparation, topical photosensitizer application, incubation time, light source exposure. Recently fractional ablative lasers have proven quite effective in allowing a much better trans-cutaneous penetration and more uniform photosensitizer distribution within selected skin areas. PpIX tissue accumulation after photosensitizer conversion varies according to original pharmacologic concentration and incubation time. PDT effect needs proper concentrations of tissue oxygen to achieve higher levels of ROS-associated results. Two types of irradiation techniques have been used to activate PDT effects: continuous and sequential exposures. Continuous exposure is easier but less effective since tissue oxygen reduces its concentration during irradiation due to increased tissue edema. Sequential exposures allow tissue oxygen reservoirs to replenish during resting intervals. Warming tissue during intervals using long pulse IR lasers can potentially increase tissue oxygen levels further improving PDT effects. Strategic combinations of ancillary techniques can lead to better and more reproducible clinical results.

St. Josef-Hospital, Germany

Skåne University Hospital, Sweden
Since 1990 our Laser & Vascular Anomaly clinic has been treated vascular malformations and tumours with lasers and since 1998 IPL as an adjuvant tool. Appropriate treatment begins with the correct diagnosis. Therefore ISSVA´s classifications are of extreme importance.
Capillary malformations responds well but needs a lot of treatments and it is rare with total blanching. Maintenance treatments.
Venous malformation, especially focal and smaller and less deep thatn7 mm responds well with long pulsed Nd:YAG laser with cold air but needs several treatments and need sometimes combination with surgery or sclerotherapy. Maintenance treatments usually. Blue Rubber Blebs should be treated as early as possible to prevent growth to larger lesions.
Infantile Hemangiomas (IH): In a retrospective study 2000 -2006 of the treatment of superficial small ones, we found that out of 283 we treated only 109. Treatments were given until sign of regression which in average was seen after 3 treatments in 88 % of the patients. Maximum 6 treatments. 39 % needed additional treatments e.g. steroids, surgery. No side effects were seen in 80% of the patients.
Since 2008 we have been using Propranolol systemically in severe cases with excellent results. Therefore, we do much less lasers and/IPL of IH. Ulcerated IH, very superficial IH and when there is a contra indication for systemic propranolol or when parents refuse systemic propranolol ,we often treat with laser or IPL in combination with topical propranolol with very good results but slower effect than with systemic treatment. We only recommend laser and IPL treatments if the physician is an expert in vascular anomalies as well as expert in lasers.
Machines that have been used are: IPL VL 555 -950 nm, 9 ms , 15 -17 J/cm2 and PR 535 – 750 nm , PDL 10 mm spot, 10 ms, 8 J/cm2 , diode 910 nm and long pulsed Nd:YAG cold air , 3 ms , 32 ms , 254 -300 J/cm2.
A multidisciplinary vascular lesion team is highly recommended when determining appropriate therapeutic strategies and our group who has worked together since 1994 also now has telemedicine with videoconference unit connected to a multi conference unit where specialists from other sites can connect for participation. The conference room includes workstations for the disciplines showing images like CT/MR, histological images, visual light images but also patient record text.

University Hospital of Zurich, Switzerland

University Hospital of Zurich, Switzerland

Erasmus Medical Center, Netherlands
Microcystic adnexal carcinoma is a rare low-grade malignant adnexal tumor that usually affects middle aged and older adults. It took until 1982, when the tumor was first described by Goldstein. The exact pathogenesis is still unknown, but experts suggest that a pluripotent stem cell, that is able to differentiate further into sweat glands, is responsible for this tumor. The tumor is mainly located in the face. The clinical presentation is not specific and mostly clinically misdiagnosed as basal cell carcinoma. The tumor tends to have a quite extensive subclinical involvement and therefore Mohs micrographic surgery is the treatment of choice. Mohs micrographic surgery has better cure rates than wide local excision. Especially in cases of perineural invasion, which is quite often the case in this kind of tumors, the tumor can be treated with Mohs micrographic surgery. I will focus on a larger series of previously biopsied microcystic adnexal carcinomas, which were operated between 2010 and 2017 at Erasmus MC. In only half of the cases, the diagnosis microcystic adnexal carcinoma could be confirmed during and after surgery. In most of the cases in which the tumor was a different kind of cutaneous malignancy, this has been without consequences. On the other hand, especially the misdiagnosis of syringoma is potentially dangerous and can lead to large defects for a benign lesion.

Geneva University Hospitals - HUG, Switzerland

University Hospital of Zurich, Switzerland

Inselspital, Germany
Eckart Haneke
Dept Dermatol, Inselspital, Univ Bern, Switzerland
Dermatol Practice Dermaticum, Freiburg, Germany
Centro Dermatol Epidermis, Inst Cuf, Porto, Portugal
Dept Dermatol, Univ Hosp, Gent, Belgium
Many surgical interventions on the nails leave a defect and many of these defects are challenging to close. Secondary intention healing may be an option and often gives good aesthetic and functional results. Direct closure with suture is restricted to very small and ideally located defects of the nail unit. In contrast, free grafts very often yield excellent results both considering function as well as cosmesis. Their unsurpassed advantage in nail cancer surgery, however, is that tumor removal is not hampered by fear of a large defect, which cannot be closed. Depending on the nature of the defect and its specific localization within the nail organ’s subunits, various grafts are appropriate. Split-thickness skin grafts are good for small to medium-sized defects of the proximal nail fold not reaching its free margin and the hyponychium. Large defects including the proximal and lateral nail folds are repaired with a full-thickness skin graft. Nailbed defects can be closed with a reversed dermal graft that often takes on nailbed characterists in contrast to split and full-thickness grafts. Finally, grafts are a good option for defects in special localizations. Lateral defects including the lateral matrix and nailbed with or without the lateral nail fold are excised in the manner of a lateral longitudinal nail excision; a bridge flap from the lateral aspect of the distal phalanx permits the defect to be sutured with ease. Transposition flaps are ideal for defects of the proximal nailfold after myxoid cyst resection, but also after extirpation of small cancers. The use of matrix and nailbed flaps in cancer surgery is limited as they only allow very small defects to be covered.
Many options exist in nail surgery to achieve a satisfactory result after tumor removal.

Erasmus Medical Center, Netherlands

Geneva University Hospitals - HUG, Switzerland

Contact Us
We look forward to hearing from you.